ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer

Diffuse-type gastric cancer (DGC) accounts for approximately one-third of gastric cancer cases, but it is clinically more aggressive and associated with poorer survival prognosis compared to intestinal-type gastric cancer (IGC). Our study revealed significantly reduced ESRP1 expression in DGC patients relative to IGC counterparts, with its high expression positively correlating with DGC patient prognosis. Both in vitro and in vivo experimental models demonstrated that ESRP1 has the ability to hinder the malignant progression of DGC. Mechanistically, ESRP1 interacts with DHCR7, a ferroptosis-promoting regulator, thereby upregulating DHCR7 expression and enhancing ferroptosis susceptibility in DGC cells. In DGC patients with high ESRP1 expression, ferroptosis-inducing therapy emerges as a promising treatment alternative. Moreover, for ESRP1-low DGC cases, we identified several potent small-molecule drugs. These findings collectively position ESRP1 as a potential therapeutic target for DGC intervention.

Authors

Institutions

Publication Details

Journal
Journal of Experimental & Clinical Cancer Research
Published
2025-06-18
DOI
https://doi.org/10.1186/s13046-025-03435-2
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer

Xinyu Liu, Xiaoling Cui, Wei Chong, Yaodong Sang et al.
Journal of Experimental & Clinical Cancer Research
Ferroptosis and cancer prognosis
article

ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer

Xinyu Liu, Xiaoling Cui, Wei Chong, Yaodong Sang, Liang Shang, Hao Chen, Xiaohan Wang, Leping Li, Kang Xu, Li Han, Xingyu Zhu, Baoshan Cai
article en

Abstract

Diffuse-type gastric cancer (DGC) accounts for approximately one-third of gastric cancer cases, but it is clinically more aggressive and associated with poorer survival prognosis compared to intestinal-type gastric cancer (IGC). Our study revealed significantly reduced ESRP1 expression in DGC patients relative to IGC counterparts, with its high expression positively correlating with DGC patient prognosis. Both in vitro and in vivo experimental models demonstrated that ESRP1 has the ability to hinder the malignant progression of DGC. Mechanistically, ESRP1 interacts with DHCR7, a ferroptosis-promoting regulator, thereby upregulating DHCR7 expression and enhancing ferroptosis susceptibility in DGC cells. In DGC patients with high ESRP1 expression, ferroptosis-inducing therapy emerges as a promising treatment alternative. Moreover, for ESRP1-low DGC cases, we identified several potent small-molecule drugs. These findings collectively position ESRP1 as a potential therapeutic target for DGC intervention.

Journal of Experimental & Clinical Cancer ResearchVol. 44(1)
Shandong University (CN), Shandong Provincial Hospital (CN), Qilu Hospital of Shandong University (CN), First Affiliated Hospital of Jinan University (CN), Shandong First Medical University (CN)
National Natural Science Foundation of China, Key Technology Research and Development Program of Shandong
No poverty
Openalex Percentile: Top 77%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.